ABVC BioPharma, Inc. (ABVC): Price and Financial Metrics

ABVC BioPharma, Inc. (ABVC): $1.20

0.01 (-0.83%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add ABVC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#317 of 357

in industry

ABVC Price/Volume Stats

Current price $1.20 52-week high $9.60
Prev. close $1.21 52-week low $0.67
Day low $1.15 Volume 78,600
Day high $1.25 Avg. volume 2,909,246
50-day MA $1.31 Dividend yield N/A
200-day MA $2.60 Market Cap 9.29M

ABVC Stock Price Chart Interactive Chart >

ABVC POWR Grades

  • ABVC scores best on the Growth dimension, with a Growth rank ahead of 85.68% of US stocks.
  • ABVC's strongest trending metric is Growth; it's been moving up over the last 107 days.
  • ABVC ranks lowest in Stability; there it ranks in the 1st percentile.

ABVC Stock Summary

  • ABVC BIOPHARMA INC's stock had its IPO on August 3, 2021, making it an older stock than just 4.87% of US equities in our set.
  • As for revenue growth, note that ABVC's revenue has grown 115.53% over the past 12 months; that beats the revenue growth of 96.03% of US companies in our set.
  • The volatility of ABVC BIOPHARMA INC's share price is greater than that of 96.47% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to ABVC BIOPHARMA INC, a group of peers worth examining would be HCAT, RCAT, CCCS, ZUO, and ACCD.
  • Visit ABVC's SEC page to see the company's official filings. To visit the company's web site, go to www.ambrivis.com.

ABVC Valuation Summary

  • In comparison to the median Healthcare stock, ABVC's price/sales ratio is 171.43% higher, now standing at 11.4.
  • ABVC's price/sales ratio has moved down 107.8 over the prior 29 months.

Below are key valuation metrics over time for ABVC.

Stock Date P/S P/B P/E EV/EBIT
ABVC 2023-12-29 11.4 0.9 -0.7 -1.1
ABVC 2023-12-28 12.2 1.0 -0.7 -1.2
ABVC 2023-12-27 11.8 1.0 -0.7 -1.1
ABVC 2023-12-26 11.9 1.0 -0.7 -1.1
ABVC 2023-12-22 10.6 0.9 -0.6 -1.0
ABVC 2023-12-21 10.8 0.9 -0.7 -1.1

ABVC BioPharma, Inc. (ABVC) Company Bio


American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.


ABVC Latest News Stream


Event/Time News Detail
Loading, please wait...

ABVC Latest Social Stream


Loading social stream, please wait...

View Full ABVC Social Stream

Latest ABVC News From Around the Web

Below are the latest news stories about ABVC BIOPHARMA INC that investors may wish to consider to help them evaluate ABVC as an investment opportunity.

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

FREMONT, CA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase II part II clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. A total of 94 subjects were screened, out of whi

Yahoo | December 7, 2023

ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials

FREMONT, CA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today shared an interview with Dr. Scott Irwin, MD, Ph.D., an eminent Professor of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center (CSMC). Dr. Irwin serves as the Principal Investigator for the clinical trials of ABV-1601,

Yahoo | December 5, 2023

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a U.S. patent, Application No. 17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder (

Yahoo | November 21, 2023

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivit

Yahoo | November 16, 2023

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023. These results, including the financial statements included herein, can be found in the Company's Quarterly Report on Form 10-Q that was filed earlier today with t

Yahoo | November 15, 2023

Read More 'ABVC' Stories Here

ABVC Price Returns

1-mo -7.69%
3-mo -28.57%
6-mo -9.77%
1-year -82.73%
3-year -97.13%
5-year N/A
YTD 3.45%
2023 -81.44%
2022 -81.56%
2021 -33.53%
2020 16.70%
2019 -87.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!